April 2026 - MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia

The TGA registration establishes Minjuvi as the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for this group of patients.